These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 23127558)
21. Roles for CSN5 in control of p53/MDM2 activities. Zhang XC; Chen J; Su CH; Yang HY; Lee MH J Cell Biochem; 2008 Mar; 103(4):1219-30. PubMed ID: 17879958 [TBL] [Abstract][Full Text] [Related]
22. Suppression of CSN5 promotes the apoptosis of gastric cancer cells through regulating p53-related apoptotic pathways. Sang MM; Du WQ; Zhang RY; Zheng JN; Pei DS Bioorg Med Chem Lett; 2015 Aug; 25(15):2897-901. PubMed ID: 26048783 [TBL] [Abstract][Full Text] [Related]
23. CSN5 controls the growth of osteosarcoma via modulating the EGFR/PI3K/Akt axis. Wan Z; Huang S; Mo F; Yao Y; Liu G; Han Z; Chen M; Zhiyun L Exp Cell Res; 2019 Nov; 384(2):111646. PubMed ID: 31560888 [TBL] [Abstract][Full Text] [Related]
24. Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response. Lee YH; Judge AD; Seo D; Kitade M; Gómez-Quiroz LE; Ishikawa T; Andersen JB; Kim BK; Marquardt JU; Raggi C; Avital I; Conner EA; MacLachlan I; Factor VM; Thorgeirsson SS Oncogene; 2011 Oct; 30(40):4175-84. PubMed ID: 21499307 [TBL] [Abstract][Full Text] [Related]
25. Targeted inactivation of the COP9 signalosome impairs multiple stages of T cell development. Panattoni M; Sanvito F; Basso V; Doglioni C; Casorati G; Montini E; Bender JR; Mondino A; Pardi R J Exp Med; 2008 Feb; 205(2):465-77. PubMed ID: 18268034 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline. Pulvino M; Chen L; Oleksyn D; Li J; Compitello G; Rossi R; Spence S; Balakrishnan V; Jordan C; Poligone B; Casulo C; Burack R; Shapiro JL; Bernstein S; Friedberg JW; Deshaies RJ; Land H; Zhao J Oncotarget; 2015 Jun; 6(17):14796-813. PubMed ID: 26142707 [TBL] [Abstract][Full Text] [Related]
27. The putative oncotarget CSN5 controls a transcription-uncorrelated p53-mediated autophagy implicated in cancer cell survival under curcumin treatment. Zhang QY; Jin R; Zhang X; Sheng JP; Yu F; Tan RX; Pan Y; Huang JJ; Kong LD Oncotarget; 2016 Oct; 7(43):69688-69702. PubMed ID: 27626169 [TBL] [Abstract][Full Text] [Related]
28. PRAK is essential for ras-induced senescence and tumor suppression. Sun P; Yoshizuka N; New L; Moser BA; Li Y; Liao R; Xie C; Chen J; Deng Q; Yamout M; Dong MQ; Frangou CG; Yates JR; Wright PE; Han J Cell; 2007 Jan; 128(2):295-308. PubMed ID: 17254968 [TBL] [Abstract][Full Text] [Related]
30. COP9 subunits 4 and 5 target soluble guanylyl cyclase α1 and p53 in prostate cancer cells. Bhansali M; Shemshedini L Mol Endocrinol; 2014 Jun; 28(6):834-45. PubMed ID: 24725084 [TBL] [Abstract][Full Text] [Related]
31. PEA15 regulates the DNA damage-induced cell cycle checkpoint and oncogene-directed transformation. Nagarajan A; Dogra SK; Liu AY; Green MR; Wajapeyee N Mol Cell Biol; 2014 Jun; 34(12):2264-82. PubMed ID: 24710276 [TBL] [Abstract][Full Text] [Related]
32. The pivotal oncogenic role of Jab1/CSN5 and its therapeutic implications in human cancer. Guo Z; Wang Y; Zhao Y; Shu Y; Liu Z; Zhou H; Wang H; Zhang W Gene; 2019 Mar; 687():219-227. PubMed ID: 30468907 [TBL] [Abstract][Full Text] [Related]
33. Preparation and characterization of monoclonal antibodies against mouse Jab1/CSN5 protein. Kato JY; Nakamae I; Tomoda K; Fukumoto A; Yoneda-Kato N Hybridoma (Larchmt); 2006 Dec; 25(6):342-8. PubMed ID: 17203996 [TBL] [Abstract][Full Text] [Related]
34. The inhibition of Nek6 function sensitizes human cancer cells to premature senescence upon serum reduction or anticancer drug treatment. Jee HJ; Kim HJ; Kim AJ; Song N; Kim M; Lee HJ; Yun J Cancer Lett; 2013 Jul; 335(1):175-82. PubMed ID: 23416273 [TBL] [Abstract][Full Text] [Related]